Evidence map›Paper›PMID 26582203›Full record

ArticleThe Journal of biological chemistry2016

A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.

Shihui Guo, Wolfgang Skala, Viktor Magdolen, Peter Briza, Martin L Biniossek, Oliver Schilling, Josef Kellermann, Hans Brandstetter, Peter Goettig

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Drug Discovery Strategies for Kallikrein-Related Peptidases.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Non-Canonical Amino Acids in Analyses of Protease Structure and Function.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Shihui GuoFrom the Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria.
Wolfgang SkalaFrom the Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria.
Viktor Magdolenthe Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar der TU München, 81675 Munich, Germany.
Peter BrizaFrom the Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria.
Martin L Biniossekthe Institute of Molecular Medicine and Cell Research and.
Oliver Schillingthe Institute of Molecular Medicine and Cell Research and BIOSS Centre for Biological Signaling Studies, University of Freiburg, 79104 Freiburg, Germany, the German Cancer Consortium (DKTK), 69120 Heidelberg, Germany, the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany, and.
Josef Kellermannthe Max-Planck-Institute for Biochemistry, 82152 Martinsried, Germany.
Hans BrandstetterFrom the Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria.
Peter GoettigFrom the Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria, peter.goettig@sbg.ac.at.
University of Salzburg · ATDeutschen Konsortium für Translationale Krebsforschung · DEInstitute of Molecular Medicine · INKlinikum rechts der Isar · DEMax Planck Institute of Biochemistry · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human kallikrein-related peptidase 2 (KLK2) is a key serine protease in semen liquefaction and prostate cancer together with KLK3/prostate-specific antigen. In order to decipher the function of its potential N-glycosylation site, we produced pro-KLK2 in Leishmania tarentolae cells and compared it with its non-glycosylated counterpart from Escherichia coli expression. Mass spectrometry revealed that Asn-95 carries a core glycan, consisting of two GlcNAc and three hexoses. Autocatalytic activation was retarded in glyco-pro-KLK2, whereas the activated glyco-form exhibited an increased proteolytic resistance. The specificity patterns obtained by the PICS (proteomic identification of protease cleavage sites) method are similar for both KLK2 variants, with a major preference for P1-Arg. However, glycosylation changes the enzymatic activity of KLK2 in a drastically substrate-dependent manner. Although glyco-KLK2 has a considerably lower catalytic efficiency than glycan-free KLK2 toward peptidic substrates with P2-Phe, the situation was reverted toward protein substrates, such as glyco-pro-KLK2 itself. These findings can be rationalized by the glycan-carrying 99-loop that prefers to cover the active site like a lid. By contrast, the non-glycosylated 99-loop seems to favor a wide open conformation, which mostly increases the apparent affinity for the substrates (i.e. by a reduction of Km). Also, the cleavage pattern and kinetics in autolytic inactivation of both KLK2 variants can be explained by a shift of the target sites due to the presence of the glycan. These striking effects of glycosylation pave the way to a deeper understanding of kallikrein-related peptidase biology and pathology.

Indexed as

Amino Acid SequenceAutolysisEnzyme ActivationFibronectinsGlycosylationHumansKineticsModels, MolecularMolecular Sequence DataPolysaccharidesProtein Structure, SecondaryProteolysisRecombinant ProteinsStructure-Activity RelationshipSubstrate SpecificityTime FactorsFibronectinsPolysaccharidesRecombinant ProteinsTissue Kallikreinsautolytic inactivationenzyme kineticskallikreinN-linked glycosylationprostate cancerserine proteasesubstrate specificityzymogen activation

Identifiers

PMID26582203
PMCPMC4705380
OpenAlexW2232279910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.